Anti-Rheumatic Drugs - Morocco | Statista Market Forecast

The Anti-Rheumatic Drugs market in Morocco is expected to witness a significant increase in revenue, reaching a projected value of US$15.42m in 2024.
This indicates a positive growth trend in the market.
Furthermore, it is anticipated that the market will continue to expand at an annual growth rate of 1.05%, resulting in a market volume of US$16.24m by 2029.
In the global context, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market, with an estimated value of US$34.70bn in 2024.
This demonstrates the dominant position of the United States in this market.
Morocco's market for anti-rheumatic drugs is experiencing a surge in demand due to the increasing prevalence of rheumatic diseases in the aging population.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Morocco has been experiencing steady growth over the past few years.

Customer preferences: Moroccan customers are increasingly seeking out Anti-Rheumatic Drugs due to the rising prevalence of rheumatic diseases in the country. Additionally, the aging population and changing lifestyles have also contributed to the growing demand for these drugs. Customers in Morocco tend to prefer generic versions of Anti-Rheumatic Drugs due to their affordability.

Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in Morocco is the increasing availability of biosimilars. These drugs are becoming more widely available due to the expiration of patents on older biologic drugs. Additionally, there is a growing trend towards the use of combination therapies, which involve the use of multiple drugs to treat rheumatic diseases. This approach has been shown to be more effective in managing symptoms than using a single drug.

Local special circumstances: Morocco has a relatively low GDP per capita compared to other countries in the region. This has led to a focus on affordable healthcare solutions, including the use of generic drugs. Additionally, the Moroccan government has implemented policies to increase access to healthcare, which has contributed to the growing demand for Anti-Rheumatic Drugs.

Underlying macroeconomic factors: Morocco has a growing economy, with a focus on developing its healthcare sector. The country has been investing in healthcare infrastructure and implementing policies to increase access to healthcare services. Additionally, the rising prevalence of rheumatic diseases in the country has contributed to the growing demand for Anti-Rheumatic Drugs. The aging population and changing lifestyles have also played a role in the increasing demand for these drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.